Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

14-3-3ΞΆ Overexpression is Associated with Poor Prognosis in Ovarian Cancer.

Kim HJ, Sung SH, Kim CY, Bae MK, Cho MS, Kim YH, Kim SC, Ju W.

Yonsei Med J. 2018 Jan;59(1):51-56. doi: 10.3349/ymj.2018.59.1.51.

2.

Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Stewart SL, Harewood R, Matz M, Rim SH, Sabatino SA, Ward KC, Weir HK.

Cancer. 2017 Dec 15;123 Suppl 24:5138-5159. doi: 10.1002/cncr.31027.

PMID:
29205312
3.

Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC Jr.

Ultrasound Obstet Gynecol. 2018 Mar;51(3):293-303. doi: 10.1002/uog.17557. No abstract available.

PMID:
28639753
4.

Complications from Surgeries Related to Ovarian Cancer Screening.

Baldwin LA, Pavlik EJ, Ueland E, Brown HE, Ladd KM, Huang B, DeSimone CP, van Nagell JR, Ueland FR, Miller RW.

Diagnostics (Basel). 2017 Mar 8;7(1). pii: E16. doi: 10.3390/diagnostics7010016.

5.

Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.

Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E, Piccirilli JA.

Cancer Res. 2017 Apr 1;77(7):1684-1696. doi: 10.1158/0008-5472.CAN-16-1454. Epub 2017 Feb 15.

6.

Use of Biomarkers in Screening for Cancer.

Duffy MJ.

EJIFCC. 2010 Mar 25;21(1):1-12. eCollection 2010 Mar.

7.

Management of relapsed ovarian cancer: a review.

Giornelli GH.

Springerplus. 2016 Jul 28;5(1):1197. doi: 10.1186/s40064-016-2660-0. eCollection 2016. Review.

8.

Chinese Obstetrics & Gynecology journal club: a randomised controlled trial.

Tsui IK, Dodson WC, Kunselman AR, Kuang H, Han FJ, Legro RS, Wu XK.

BMJ Open. 2016 Jan 28;6(1):e010178. doi: 10.1136/bmjopen-2015-010178.

9.

Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.

Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, Jacobs I, Timms JF.

Biomed Res Int. 2015;2015:681416. doi: 10.1155/2015/681416. Epub 2015 Dec 24.

10.

The Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality.

Stewart SL, Cooney D, Hirsch S, Westervelt L, Richards TB, Rim SH, Thomas CC.

World J Obstet Gynecol. 2014 May;3(2):71-77. Epub 2014 May 10.

11.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.

12.

Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.

Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I.

J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.

13.

Ovarian cancer risk reduction through opportunistic salpingectomy.

Kwon JS.

J Gynecol Oncol. 2015 Apr;26(2):83-6. doi: 10.3802/jgo.2015.26.2.83. No abstract available.

14.

Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.

Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM.

PLoS One. 2015 Mar 23;10(3):e0121112. doi: 10.1371/journal.pone.0121112. eCollection 2015.

15.

The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.

Chang KE, Wei BR, Madigan JP, Hall MD, Simpson RM, Zhuang Z, Gottesman MM.

Mol Cancer Ther. 2015 Jan;14(1):90-100. doi: 10.1158/1535-7163.MCT-14-0496. Epub 2014 Nov 5.

16.

In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Cohen JG, White M, Cruz A, Farias-Eisner R.

World J Biol Chem. 2014 Aug 26;5(3):286-300. doi: 10.4331/wjbc.v5.i3.286. Review.

17.

Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.

Bodelon C, Pfeiffer RM, Buys SS, Black A, Sherman ME.

J Natl Cancer Inst. 2014 Sep 13;106(10). pii: dju262. doi: 10.1093/jnci/dju262. Print 2014 Oct.

18.

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, Whelan RJ, Patankar MS.

Mol Cancer. 2014 May 29;13:129. doi: 10.1186/1476-4598-13-129. Review.

19.
20.

Accuracy of ovarian and colon cancer risk assessments by U.S. physicians.

Baldwin LM, Trivers KF, Andrilla CH, Matthews B, Miller JW, Lishner DM, Goff BA.

J Gen Intern Med. 2014 May;29(5):741-9. doi: 10.1007/s11606-014-2768-2. Epub 2014 Feb 12.

Supplemental Content

Support Center